Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer

Clinical trial NCT03647488 · COMPLETED

Trial details

NCT number: NCT03647488
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung

Start date: 2018-12-26
Primary completion: 2020-09-07
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.